| Symbol | TCRX |
|---|---|
| Name | TSCAN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 830 WINTER STREET, WALTHAM, Massachusetts, 02451, United States |
| Telephone | +1 857 399-9500 |
| Fax | — |
| — | |
| Website | https://www.tscan.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001783328 |
| Description | TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The companys lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. Additional info from NASDAQ: |
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Read moreTScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
Read moreCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Read moreBAKER BROS. ADVISORS LP 🟢 acquired 134.0K shares (2 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236870
Read more(99% Neutral) TSCAN THERAPEUTICS, INC. (TCRX) Announces Regulatory Update
Read moreWoods Keith 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236855
Read moreGruia Gabriela 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236848
Read moreDorton Katina 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236844
Read moreKlencke Barbara 🟢 acquired 67.0K shares (1 derivative) of TScan Therapeutics, Inc. (TCRX) at $0.99 Transaction Date: May 20, 2026 | Filing ID: 236841
Read more(30% Negative) TSCAN THERAPEUTICS, INC. (TCRX) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07702578 | A Phase 3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergo… | Phase3 | AML | Recruiting | 2026-06-18 | 2029-06-01 | ClinicalTrials.gov |
| NCT06976736 | A Long Term Follow-up Study of TScan TCR-T Products | — | AML | Recruiting | 2025-09-09 | 2040-09-01 | ClinicalTrials.gov |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With L… | Phase1 | Head and Neck Cancer | Active_Not_Recruiting | 2024-05-06 | 2026-12-30 | ClinicalTrials.gov |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity … | — | Head and Neck Cancer | Active_Not_Recruiting | 2023-06-26 | 2027-01-14 | ClinicalTrials.gov |
| NCT06587828 | A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Ce… | — | Autoimmune Diseases | Recruiting | 2023-01-03 | 2027-01-01 | ClinicalTrials.gov |
| NCT05473910 | A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Under… | Phase1 | AML | Recruiting | 2022-11-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT05230186 | A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibito… | — | Solid Tumor, Adult | Unknown | 2021-02-26 | 2024-12-23 | ClinicalTrials.gov |
| NCT04680416 | Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Respondin… | — | Renal Clear Cell Carcinoma | Withdrawn | 2020-12-17 | 2021-08-04 | ClinicalTrials.gov |
| NCT04397900 | Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to I… | — | Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection | Completed | 2020-04-09 | 2021-04-12 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Control | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| TSC-101 | Other | Phase PHASE3 | AML | RECRUITING | NCT07702578 |
| Observational | Other | Preclinical | AML | RECRUITING | NCT06976736 |
| Tumor Biopsy | Other | Preclinical | Solid Tumor, Adult | UNKNOWN | NCT05230186 |
| TSC-201-B0702 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-202-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-201-B0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-203-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-C0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 | Other | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| Tumor and HLA Profiling | Other | Preclinical | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05812027 |
| Companion blood samples with procedure | Procedure | Preclinical | Autoimmune Diseases | RECRUITING | NCT06587828 |
| Control | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | Other | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Observational | OTHER | Preclinical | AML | RECRUITING | NCT06976736 |
| Companion blood samples with procedure | PROCEDURE | Preclinical | Autoimmune Diseases | RECRUITING | NCT06587828 |
| TSC-201-B0702 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-202-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-201-B0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0101 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-203-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 + TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 + TSC-204-C0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-200-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-C0702 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| TSC-204-A0201 | BIOLOGICAL | Phase PHASE1 | Head and Neck Cancer | ACTIVE_NOT_RECRUITING | NCT05973487 |
| Control | OTHER | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-101 | DRUG | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| SOC + TSC-100 | DRUG | Phase PHASE1 | AML | RECRUITING | NCT05473910 |
| Tumor Biopsy | PROCEDURE | Preclinical | Solid Tumor, Adult | UNKNOWN | NCT05230186 |